Nature Communications (Oct 2022)
Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke
- Lingyan Chen,
- James E. Peters,
- Bram Prins,
- Elodie Persyn,
- Matthew Traylor,
- Praveen Surendran,
- Savita Karthikeyan,
- Ekaterina Yonova-Doing,
- Emanuele Di Angelantonio,
- David J. Roberts,
- Nicholas A. Watkins,
- Willem H. Ouwehand,
- John Danesh,
- Cathryn M. Lewis,
- Paola G. Bronson,
- Hugh S. Markus,
- Stephen Burgess,
- Adam S. Butterworth,
- Joanna M. M. Howson
Affiliations
- Lingyan Chen
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- James E. Peters
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Bram Prins
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Elodie Persyn
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Matthew Traylor
- Department of Genetics, Novo Nordisk Research Centre Oxford
- Praveen Surendran
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Savita Karthikeyan
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Ekaterina Yonova-Doing
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Emanuele Di Angelantonio
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- David J. Roberts
- National Institute for Health and Care Research Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge
- Nicholas A. Watkins
- NHS Blood and Transplant, Cambridge Biomedical Campus
- Willem H. Ouwehand
- British Heart Foundation Centre of Research Excellence, University of Cambridge
- John Danesh
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Cathryn M. Lewis
- Department of Medical and Molecular Genetics, King’s College London
- Paola G. Bronson
- R&D Translational Biology, Biogen, Inc.
- Hugh S. Markus
- Department of Clinical Neurosciences, University of Cambridge
- Stephen Burgess
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Adam S. Butterworth
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- Joanna M. M. Howson
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge
- DOI
- https://doi.org/10.1038/s41467-022-33675-1
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Mendelian randomization can be used to mimic the effects of protein-targeting drugs in a population of individuals. Here, the authors have identified potential causal proteins for stroke in a two-sample Mendelian randomization framework, providing potential stroke therapeutic targets.
